Los puntos clave no están disponibles para este artículo en este momento.
Obeticholic acid (OCA) treatment for primary biliary cholangitis (PBC) was conditionally approved in the phase 3 POISE trial. The COBALT confirmatory trial assessed whether clinical outcomes in patients with PBC improve with OCA therapy.
Kowdley et al. (Wed,) studied this question.